Who makes MIN-117 5.0 mg?

MIN-117 5.0 mg is developed by Minerva Neurosciences.

What are the side effects of MIN-117 5.0 mg?

Common side effects include Headache.

Last reviewed 2026-04-20 · How we verify

MIN-117 5.0 mg

Minerva Neurosciences · Phase 2 active Small molecule Quality 5/100

At a glance

Generic name	MIN-117 5.0 mg
Sponsor	Minerva Neurosciences
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

Headache

Key clinical trials

A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MIN-117 5.0 mg CI brief — competitive landscape report
MIN-117 5.0 mg updates RSS · CI watch RSS
Minerva Neurosciences portfolio CI